|Articles|November 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-11-01-2012
  • Volume 21
  • Issue 11

Survey Results of Start-Up Cycle Times

Author(s)Tufts, CSDD

Tufts CSDD

A 2012 study conducted by the Tufts Center for the Study of Drug Development shows that academic centers and hospitals take significantly longer to initiate industry-funded clinical trials. Overall, it takes an AMC or hospital more than one year (12.9 months) on average from the pre-study visit to first patient in (FPI) the clinical trial. This compares with 7.9 months for community-based physician practices to complete the same cycle—nearly a 40% time reduction. The Tufts CSDD study evaluated start-up cycle times for 5,296 investigative sites participating in 105 Phase II and III clinical trials. The largest bottleneck is the time from when the contract is received by the center to the time that the contract is executed. AMCs and hospitals take nearly 73% longer than their for-profit counterparts—4.1 months on average versus 1.1 months. Cycle times from contract execution to site initiation, and from site initiation to FPI for non- and for-profit investigative sites are much closer, suggesting that AMCs and hospitals perform more competitively once they get through their less efficient administrative tasks.

Figure 1

—Tufts Center for the Study of Drug Development, https://csdd.tufts.edu

Articles in this issue

almost 14 years ago

Act Cover

almost 14 years ago

Business and News Update November 2012

almost 14 years ago

Act Insert cover

almost 14 years ago

Pediatric Drug Development

almost 14 years ago

ePRO Industry Growth

almost 14 years ago

Generic Drugs Making Waves

almost 14 years ago

Are CRCs Reaching Their Tipping Point?

almost 14 years ago

EMA's Mid-Year Report Merits Scrutiny

Related to this article

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.